HopeStage
Back to all studies
RecruitingNCT06238700

Pregnenolone or placebo for perimenopausal depression

About this titleRead the official source — NCT06238700
Placebo comparisonAges 40–60United States
The study in practice

Understand this study

Who could participate?

Listed age limits: 40 years to 60 years.

What will I do during this study?

Participants take pregnenolone or placebo (an inactive comparison treatment) twice daily for four weeks. The study examines behavioral and brain measures during the menopause transition.

Listed locations
BostonSee all locations and recruitment

Get this study by email

HopeStage may email me about this study.
Loading the security check...

What to know before participating

A point to clarify

This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?

Study clarity

Things to check before joining

Study start dateStarted: May 1, 2026
Recruitment status
Recruiting
Enrollment listed in the registry
80
Sponsor
Beth Israel Deaconess Medical Center
Sponsor type
Hospital / academic medical center
Study type
Other
Intervention type
Dietary supplement, Other
Locations
United States
Age range
From 40 Years to 60 Years
Official registry ID
NCT06238700
Official title
Show the full official title

Targeting Allopregnanolone to Probe Behavioral and Neurobiological Mechanisms That Underlie Depression in Women Across the Menopause Transition

Recruitment & locations

Currently recruiting

Boston

Interested in joining this study?

HopeStage may email me about this study.
Loading the security check...
FAQ

Questions about this study

Who is behind this study?

The study sponsor is Beth Israel Deaconess Medical Center, a hospital or academic medical center.

Who can participate?

Listed age limits: 40 years to 60 years.

Is this study still recruiting?

The registry lists this study as recruiting.

Want to explore more studies?

Explore studies